Nonalcoholic fatty liver disease and the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis: the hidden danger.


Journal

Scandinavian journal of gastroenterology
ISSN: 1502-7708
Titre abrégé: Scand J Gastroenterol
Pays: England
ID NLM: 0060105

Informations de publication

Date de publication:
Mar 2021
Historique:
pubmed: 19 1 2021
medline: 19 8 2021
entrez: 18 1 2021
Statut: ppublish

Résumé

Nonalcoholic fatty liver disease (NAFLD) has been identified as risk factor for several diseases; however, its association with post endoscopic retrograde cholangiopancreatography pancreatitis (PEP) has not been studied. To assess whether NAFLD is a risk factor for the development of PEP. We performed a retrospective multicenter study. All patients who underwent ERCP during 2013-2016 at either the Shaare Zedek Medical Center in Jerusalem or EMMS Nazareth hospital and who had a diagnosis of NAFLD by abdominal imaging were eligible for inclusion. Four hundred and one patients were included, among them, 38 (9.5%) were diagnosed with PEP according to clinical, laboratory and radiological criteria. In univariate analysis, the following risk factors were associated with increased risk for PEP; Fatty liver (OR 2.363, NAFLD was shown to be a risk factor for PEP. Therefore, we suggest considering prophylactic pancreatic stenting and/or NSAID's suppositories among these patients.

Sections du résumé

BACKGROUND BACKGROUND
Nonalcoholic fatty liver disease (NAFLD) has been identified as risk factor for several diseases; however, its association with post endoscopic retrograde cholangiopancreatography pancreatitis (PEP) has not been studied.
AIMS OBJECTIVE
To assess whether NAFLD is a risk factor for the development of PEP.
METHODS METHODS
We performed a retrospective multicenter study. All patients who underwent ERCP during 2013-2016 at either the Shaare Zedek Medical Center in Jerusalem or EMMS Nazareth hospital and who had a diagnosis of NAFLD by abdominal imaging were eligible for inclusion. Four hundred and one patients were included, among them, 38 (9.5%) were diagnosed with PEP according to clinical, laboratory and radiological criteria.
RESULTS RESULTS
In univariate analysis, the following risk factors were associated with increased risk for PEP; Fatty liver (OR 2.363,
CONCLUSION CONCLUSIONS
NAFLD was shown to be a risk factor for PEP. Therefore, we suggest considering prophylactic pancreatic stenting and/or NSAID's suppositories among these patients.

Identifiants

pubmed: 33460351
doi: 10.1080/00365521.2020.1871507
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

369-373

Auteurs

Wisam Sbeit (W)

Department of Gastroenterology, Galilee Medical Center, Nahariya, Israel.
Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel.

Tawfik Khoury (T)

Department of Gastroenterology, Galilee Medical Center, Nahariya, Israel.
Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel.
Gastroenterology and endoscopy Units, The Nazareth Hospital, EMMS, Nazareth, Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel.

Dov Wengrower (D)

Department of gastroenterology and liver diseases, Faculty of Medicine, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.

Dan M Livovsky (DM)

Department of gastroenterology and liver diseases, Faculty of Medicine, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.

Bashar Fteiha (B)

Department of gastroenterology and liver diseases, Faculty of Medicine, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.

Adi Nubani (A)

Department of gastroenterology and liver diseases, Faculty of Medicine, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.

Eran Goldin (E)

Department of gastroenterology and liver diseases, Faculty of Medicine, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.

Mahmud Mahamid (M)

Department of gastroenterology and liver diseases, Faculty of Medicine, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH